AXIM Biotechnologies, Inc. announced that its scientific team has completed the optimization of a rapid diagnostics test for the quantitative measurement of Ocular Immunoglobulin E, a biomarker for ocular allergies. The test is a simple, rapid, and non-invasive immuno-chromatographic test that enables the identification of allergic conjunctivitis in one single step. This quantitative test is the only FDA-cleared and reimbursable rapid test for IgE and is of high clinical utility in the confirmation of the presence of active ocular allergens.

AXIM acquired the technology for this test and has since been optimizing the test to provide quicker and more accurate results. The test when acquired was a 15-minute test and the development team has been able to miniaturize the test and reduce time to result to seven minutes. Although approximately 40% of the general population experiences allergic conjunctivitis, it is often underdiagnosed and consequently undertreated due to the lack of diagnostic tools.

AXIM's rapid IgE test helps in the assessment of total tear IgE levels and is useful for the clinical diagnosis of allergic conjunctivitis and its severity. The presence of an allergen often mimics the signs and symptoms of Dry Eye Syndrome associated with aqueous deficiency and evaporative dry eye or both.